Literature DB >> 26450879

Targeting the tumor niche to treat cancer.

Sattva S Neelapu1, Padmanee Sharma2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26450879      PMCID： PMC4620886          DOI： 10.1073/pnas.1517389112

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


× No keyword cloud information.
  20 in total

1.  Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma.

Authors:  Anas Younes; Yasuhiro Oki; Peter McLaughlin; Amanda R Copeland; Andre Goy; Barbara Pro; Lei Feng; Ying Yuan; Hubert H Chuang; Homer A Macapinlac; Fredrick Hagemeister; Jorge Romaguera; Felipe Samaniego; Michelle A Fanale; Bouthaina Shbib Dabaja; Maria A Rodriguez; Nam Dang; Larry W Kwak; Sattva S Neelapu; Luis E Fayad
Journal:  Blood       Date:  2012-02-27       Impact factor: 22.113

2.  The CD4+CD26- T-cell population in classical Hodgkin's lymphoma displays a distinctive regulatory T-cell profile.

Authors:  Yue Ma; Lydia Visser; Tjasso Blokzijl; Geert Harms; Cigdem Atayar; Sibrand Poppema; Anke van den Berg
Journal:  Lab Invest       Date:  2008-03-24       Impact factor: 5.662

Review 3.  CD45 (leucocyte common antigen) expression in T and B lymphocyte subsets.

Authors:  S Poppema; R Lai; L Visser; X J Yan
Journal:  Leuk Lymphoma       Date:  1996-01

4.  Antibodies targeting human OX40 expand effector T cells and block inducible and natural regulatory T cell function.

Authors:  Kui S Voo; Laura Bover; Megan L Harline; Long T Vien; Valeria Facchinetti; Kazuhiko Arima; Larry W Kwak; Yong J Liu
Journal:  J Immunol       Date:  2013-09-06       Impact factor: 5.422

Review 5.  Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment.

Authors:  Christian Steidl; Joseph M Connors; Randy D Gascoyne
Journal:  J Clin Oncol       Date:  2011-04-11       Impact factor: 44.544

6.  A pilot study of rituximab in patients with recurrent, classic Hodgkin disease.

Authors:  Anas Younes; Jorge Romaguera; Frederick Hagemeister; Peter McLaughlin; Maria Alma Rodriguez; Paolo Fiumara; Andre Goy; Sima Jeha; John T Manning; Dan Jones; Lynne V Abruzzo; L Jeffrey Medeiros
Journal:  Cancer       Date:  2003-07-15       Impact factor: 6.860

Review 7.  Modulation of IL-2Rα with daclizumab for treatment of multiple sclerosis.

Authors:  Heinz Wiendl; Catharina C Gross
Journal:  Nat Rev Neurol       Date:  2013-06-04       Impact factor: 42.937

8.  Depleting tumor-specific Tregs at a single site eradicates disseminated tumors.

Authors:  Aurélien Marabelle; Holbrook Kohrt; Idit Sagiv-Barfi; Bahareh Ajami; Robert C Axtell; Gang Zhou; Ranjani Rajapaksa; Michael R Green; James Torchia; Joshua Brody; Richard Luong; Michael D Rosenblum; Lawrence Steinman; Hyam I Levitsky; Victor Tse; Ronald Levy
Journal:  J Clin Invest       Date:  2013-06       Impact factor: 14.808

9.  Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.

Authors:  Tyler R Simpson; Fubin Li; Welby Montalvo-Ortiz; Manuel A Sepulveda; Katharina Bergerhoff; Frederick Arce; Claire Roddie; Jake Y Henry; Hideo Yagita; Jedd D Wolchok; Karl S Peggs; Jeffrey V Ravetch; James P Allison; Sergio A Quezada
Journal:  J Exp Med       Date:  2013-07-29       Impact factor: 14.307

10.  Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies.

Authors:  Yannick Bulliard; Rose Jolicoeur; Maurice Windman; Sarah M Rue; Seth Ettenberg; Deborah A Knee; Nicholas S Wilson; Glenn Dranoff; Jennifer L Brogdon
Journal:  J Exp Med       Date:  2013-07-29       Impact factor: 14.307
View more
  1 in total

Review 1.  Preclinical optimization of antibody-based radiopharmaceuticals for cancer imaging and radionuclide therapy-Model, vector, and radionuclide selection.

Authors:  Lukas M Carter; Sophie Poty; Sai Kiran Sharma; Jason S Lewis
Journal:  J Labelled Comp Radiopharm       Date:  2018-03-30       Impact factor: 1.921
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.